On the 11th of February , Antonella Cardone, CEO of Cancer Patients Europe (CPE), took part in a panel discussion on “Patient Safety: Toward Protecting the Safety of Participants” at the World BI Group’s Clinical Trials Innovation Programme 2025. The symposium, held in Nice on the 11th and 12th of February, brought together a variety of experts and stakeholders in clinical research to explore innovative approaches and address critical challenges in the field. Antonella’s presentation focused on the crucial role of patient advocacy in ensuring patient safety within clinical trials. Highlighting CPE’s involvement in the EU-X-CT Clinical Trial initiative, she provided a concrete example of their active engagement in this area.
Cardone underscored that patient safety is not merely a regulatory requirement but a fundamental right, a core ethical principle that must guide all aspects of clinical research. She then went on to paint a picture of the evolving landscape of clinical research in Europe, acknowledging the transformative impact of EU initiatives promoting cross-border collaboration and enhanced patient involvement. She noted that while these developments present exciting opportunities, they also bring challenges that require careful consideration.
Referring to the current Clinical Trials Regulation, Cardone emphasised its dual focus on transparency and safety for clinical trial participants. From CPE’s perspective, both elements are inextricably linked, arguing that access to trial information empowers patients to make informed decisions about participation, allows for independent scrutiny, and promotes accountability.
While acknowledging existing initiatives, such as ACT EU and those driven by ESMO, aimed at prioritising patient safety, she emphasised the need for continued patient empowerment and asserted that the current landscape of clinical research in Europe holds promise, but realising its full potential requires amplifying the voices of patients.
Looking forward, Antonella outlined key recommendations for advancing patient safety in clinical trials, emphasising genuine patient partnerships throughout the trial lifecycle and responsible data sharing that balances transparency with individual privacy. She stressed the need for standardised safety reporting and monitoring practices, along with patient-centred safety training for researchers. Finally, she highlighted the crucial role of empowered, independent patient advocacy organisations, calling for adequate resources to support their vital work in safeguarding patient rights and promoting safety.
Antonella’s presentation served as a powerful reminder of the importance of placing patient safety at the heart of clinical research. Her recommendations provide a roadmap for ensuring that clinical trials are conducted ethically, transparently, and with the full engagement of patients.

